The combined offerings raise ~$1B in new capital, adding $500M in debt and diluting common equity by ~5.4%. The convertible notes' conversion price of ~$89.60 is a ~34% premium over the current stock price of $66.70, suggesting limited near-term conversion risk. Monitor the concurrent equity offering's completion and the impact on share price, as well as upcoming VAX-31 data readouts from OPUS-2 and OPUS-3 in H1 2027.
Price Chart
Executive Summary
Vaxcyte is raising $500M (up to $575M with overallotment) via 1.50% convertible senior notes due 2032, with a concurrent equity offering of ~7.8M shares/warrants for ~$473M. The proceeds will fund clinical development of VAX-31 (Phase 3 adult, Phase 2 infant), manufacturing scale-up, and commercial launch preparations. The filing follows positive Phase 3 OPUS-1 topline results announced on October 5, 2026, and the company reports ~$2.3B in cash as of September 30, 2026. The combined offerings add ~$1B in new capital, significantly diluting existing common stockholders via the equity component and adding $500M in debt.
Key Facts
- Offering $500M aggregate principal amount of 1.50% convertible senior notes due 2032, with underwriters' option for an additional $75M
- Initial conversion price of ~$89.60 per share, representing a ~34% premium over the October 6, 2026 closing price of $66.70
- Concurrent equity offering of 7,412,500 shares of common stock and pre-funded warrants to purchase 400,000 shares, plus up to an additional 1,171,875 shares underwriters' option
- Estimated net proceeds from the convertible note offering of ~$485.8M (or ~$558.7M if overallotment fully exercised)
- Estimated net proceeds from the concurrent equity offering of ~$473.3M (or ~$544.3M if overallotment fully exercised)
- Company expects to report cash, cash equivalents and investments of ~$2.3B as of September 30, 2026
- Proceeds to fund clinical development of VAX-31 adult and pediatric programs, manufacturing scale-up, and commercial launch preparation
- Positive Phase 3 OPUS-1 topline results announced on October 5, 2026, with VAX-31 meeting all prespecified co-primary immunogenicity endpoints
- No public market for the notes; no plans to list on any securities exchange
- Common stock listed on Nasdaq under symbol PCVX; last reported sale price of $66.70 per share on October 6, 2026
Financial Impact
Combined offerings raise ~$959M in gross proceeds ($500M notes + ~$459M equity), adding $500M in debt and diluting common equity by ~5.4% (7.8M new shares vs 144.8M outstanding). The convertible notes add $500M in debt with a 1.5% coupon, and the conversion price of ~$89.60 represents a ~34% premium over the current stock price.
Risk Factors
- Dilution from the concurrent equity offering of ~7.8M shares (5.4% of outstanding)
- Increased leverage with $500M in new debt, though at a low 1.5% coupon
- Convertible notes may trade at a discount to conversion value if stock price does not appreciate
- Execution risk on VAX-31 clinical development and commercial launch
- Potential for further equity offerings in the future, given the company's clinical-stage status
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-417984 |
| Document: d177446dexfilingfees.htm | 0001193125-26-417984 |
| Document: 0001193125-26-417984-index-headers.html | 0001193125-26-417984 |
| Document: 0001193125-26-417984-index.html | 0001193125-26-417984 |
| Document: 0001193125-26-417984.txt | 0001193125-26-417984 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $70.65 $63.68 | ▲ +9.87% | ▲ +8.37% | $59.97 (+15.12%) |
Oct 8, 2026 18d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $59.97 (+15.98%) |
Oct 8, 2026 18d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $59.97 (+15.98%) |
Oct 5, 2026 21d ago | 424B5 | $66.70 $66.80 | ▲ +0.15% | ▲ +0.29% | $59.97 (−10.09%) |
Oct 5, 2026 21d ago | 424B5 | $66.70 $66.80 | ▼ −0.15% | ▼ −0.29% | $59.97 (+10.09%) |
Oct 5, 2026 21d ago | 8-K | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $59.97 (−18.76%) |
Oct 5, 2026 21d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $59.97 (−18.76%) |
Oct 4, 2026 22d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $59.97 (−18.76%) |
Aug 5, 2026 11w ago | Insider Cluster | $58.89 $58.86 | ▼ −0.05% | ▼ −1.26% | $59.97 (+1.83%) |
Jul 6, 2026 16w ago | Insider Cluster | $60.67 $56.21 | ▼ −7.35% | ▼ −7.90% | $59.97 (−1.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers